- Trials with a EudraCT protocol (378)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18)
378 result(s) found for: Complement.
Displaying page 1 of 19.
EudraCT Number: 2019-001440-22 | Sponsor Protocol Number: 831 | Start Date*: 2019-07-28 |
Sponsor Name:Skåne University Hospital | ||
Full Title: Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting ... | ||
Medical condition: C3 glomerulopathy | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005595-35 | Sponsor Protocol Number: CHDR2036 | Start Date*: 2021-02-11 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: A dermal inflammatory challenge study to evaluate complement activation in healthy volunteers | |||||||||||||
Medical condition: Inflammation / Complement activation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005429-26 | Sponsor Protocol Number: CHDR2135 | Start Date*: 2021-12-15 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: Immunological characterization of TLR-7 mediated inflammation and complement activation after prolonged Imiquimod exposure in healthy volunteers | |||||||||||||
Medical condition: Inflammation / Complement activation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002734-20 | Sponsor Protocol Number: R3918-PNH-1852 | Start Date*: 2020-08-07 | |||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open Label, Single Arm Study to Evaluate the Efficacy and Safety of REGN3918 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Naive or Have Not Recently Re... | |||||||||||||
Medical condition: Paroxysmal nocturnal hemoglobinuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (GB - no longer in EU/EEA) HU (Completed) NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002454-78 | Sponsor Protocol Number: V72_62 | Start Date*: 2014-02-18 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics S.r.l. | |||||||||||||
Full Title: A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine when administered to Immunoco... | |||||||||||||
Medical condition: Meningococcal Group B disease. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004129-18 | Sponsor Protocol Number: AK581 | Start Date*: 2017-03-17 | ||||||||||||||||
Sponsor Name:Akari Therapeutics Plc | ||||||||||||||||||
Full Title: CONSERVE: rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study | ||||||||||||||||||
Medical condition: Paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) LT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005854-90 | Sponsor Protocol Number: ANX005-CAD-01 | Start Date*: 2021-02-11 |
Sponsor Name:Annexon, Inc. | ||
Full Title: A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Intravenous ANX005 in Participants with Primary... | ||
Medical condition: Primary Cold Agglutinin Disease (CAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004486-40 | Sponsor Protocol Number: R3918-PNH-2021 | Start Date*: 2022-04-04 | |||||||||||
Sponsor Name:REGENERON PHARMACEUTICALS, INC. | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, RAVULIZUMAB-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO A... | |||||||||||||
Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) GR (Ongoing) HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004253-24 | Sponsor Protocol Number: CLNP023B12001B | Start Date*: 2019-08-28 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy | ||
Medical condition: C3 Glomerulopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) FR (Ongoing) ES (Ongoing) DE (Ongoing) GR (Ongoing) NL (Ongoing) CZ (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001350-21 | Sponsor Protocol Number: APL2-PNH-209 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004382-13 | Sponsor Protocol Number: DANCE | Start Date*: 2019-11-28 | |||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CEMDISIRAN (ALN-CC5) FOLLOWING WITHDRAWAL OF CHRONIC ECULIZUMAB THERAPY IN PATIENTS WITH ATYP... | |||||||||||||
Medical condition: Atypical Hemolytic Uremic Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004589-21 | Sponsor Protocol Number: CLNP023B12301 | Start Date*: 2021-06-17 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy | |||||||||||||
Medical condition: complement 3 glomerulopathy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) FR (Ongoing) GR (Ongoing) BE (Completed) CZ (Completed) ES (Ongoing) IT (Ongoing) NL (Ongoing) SK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006023-39 | Sponsor Protocol Number: BI 3023_2001 | Start Date*: 2007-09-24 | |||||||||||
Sponsor Name:CSL Behring GmbH | |||||||||||||
Full Title: Pharmacokinetics of Haemocomplettan P in subjects with congenital fibrinogen deficiency | |||||||||||||
Medical condition: PK study in patient with afibrinogemia | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005731-67 | Sponsor Protocol Number: NLxxxxxxxxxx | Start Date*: 2021-07-02 | |||||||||||
Sponsor Name:Haaglanden Medisch Centrum | |||||||||||||
Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Subarachnoid Hemorrhage - A phase II trial on the safety and efficacy of C1 esterase inhibitor for the acute management of subar... | |||||||||||||
Medical condition: Subarachnoid hemorrhage | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003778-34 | Sponsor Protocol Number: VIP578 | Start Date*: 2016-01-13 | |||||||||||
Sponsor Name:Volution Immuno Pharmaceuticals (UK) Ltd | |||||||||||||
Full Title: Coversin in Paroxysmal Nocturnal Haemoglobulinuria (PNH) in patients with resistance to Eculizumab due to complement C5 Polymorphisms | |||||||||||||
Medical condition: Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in patients with resistance to Eculizumab due to complement C5 polymorphisms. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001280-30 | Sponsor Protocol Number: FGT1-A616 | Start Date*: 2007-06-20 | ||||||||||||||||
Sponsor Name:LFB SA | ||||||||||||||||||
Full Title: INTERNATIONAL NON -CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF FIBRINOGENE T-I IN ADOLESCENTS AND ADULTS WITH AFIBRINOGENAEMIA OR SEVERE HYPOFIBRINOGENAEMIA UNDERGOING SURGERY | ||||||||||||||||||
Medical condition: Surgical procedures in patients with afibrinogenaemia and severe hypofibrinogenaemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-003675-18 | Sponsor Protocol Number: ANX005-wAIHA-02 | Start Date*: 2021-01-11 | |||||||||||
Sponsor Name:Annexon, Inc. | |||||||||||||
Full Title: A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of-Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolyti... | |||||||||||||
Medical condition: Warm Autoimmune Hemolytic Anemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) BG (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001471-20 | Sponsor Protocol Number: MET35 | Start Date*: 2018-07-10 | |||||||||||
Sponsor Name:Sanofi Pasteur Inc. | |||||||||||||
Full Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age | |||||||||||||
Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003826-10 | Sponsor Protocol Number: EAGLE | Start Date*: 2014-01-24 |
Sponsor Name:IRCCS- Mario Negri Institute | ||
Full Title: EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA | ||
Medical condition: Membranoproliferative glomerulonephritis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000140-58 | Sponsor Protocol Number: NL7255100000 | Start Date*: 2020-07-23 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Complement Inhibition: Attacking the Overshooting Inflammation @fter Traumatic Brain Injury - A phase II trial on the safety and efficacy of C1 esterase inhibitor Cinryze for the acute management o... | |||||||||||||
Medical condition: Severe traumatic Brain Injury (TBI) with GCS < 13 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.